JP Morgan Maintains Neutral on Ionis Pharmaceuticals, Raises Price Target to $55
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Jessica Fye maintains a Neutral rating on Ionis Pharmaceuticals (NASDAQ:IONS) and raises the price target from $52 to $55.

February 01, 2024 | 2:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JP Morgan analyst Jessica Fye maintains a Neutral rating on Ionis Pharmaceuticals and raises the price target from $52 to $55.
The increase in the price target by a reputable analyst like Jessica Fye from JP Morgan suggests a positive outlook on the stock's value, potentially leading to short-term price appreciation. However, the maintenance of a Neutral rating indicates that there may be factors limiting significant upside or downside in the near term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100